Monograph: Casirivimab and Imdevimab

Casirivimab and Imdevimab

Die Inhalte stehen nur registrierten Benutzern zur Verfügung.

Sie sind zum ersten mal hier und möchten die Datenbank 10-Tage kostenlos testen, dann registrieren Sie sich einmalig. Nach der Registrierung melden Sie sich mit Ihrem Benutzernamen und Passwort an.

Sie sind bereits bei DrugBase registriert und möchten diese Datenbank 10-Tage kostenlos und unverbindlich testen? Dann melden Sie sich mit Ihren Zugangsdaten an und wählen Sie anschließend die Datenbank, die Sie testen möchten.

Full Title

Casirivimab and Imdevimab

Generic Name

Casirivimab; Imdevimab

INV Number

...

Synonym

...

Classification

Introduction

Introduction

...

...

Description

...

Spectrum

...

Resistance

...

Table 5. Pseudotyped VLP Neutralization Data for SARS-CoV-2 Variant Substitutions and Casirivimab and Imdevimab Together1

...

Table 6. Authentic SARS-CoV-2 Neutralization Data for Casirivimab and Imdevimab Together Using a Plaque Reduction Assay

...

...

Uses

Uses

...

Coronavirus Disease 2019 (COVID-19)

...

Emergency Use Authorization (EUA)

...

Treatment of COVID-19 in Outpatients

...

Clinical Experience

...

Treatment of COVID-19 in Hospitalized Patients

...

Clinical Experience

...

Prevention of COVID-19

...

Clinical Experience

...

...

Dosage and Administration

Dosage and Administration

...

General

...

Administration

...

Dosage and Administration Precautions

...

IV Infusion

...

Casirivimab and Imdevimab (Co-formulated)

...

Table 1. Instructions for Diluting Casirivimab and Imdevimab (Co-formulated) in 0.9% Sodium Chloride for IV Infusion1

...

Casirivimab and Imdevimab (Supplied in Separate Vials)

...

Table 2. Instructions for Combining and Diluting Casirivimab and Imdevimab (Supplied in Separate Vials) in 0.9% Sodium Chloride for IV Infusion1

...

Rate of Administration

...

Table 3. Recommended IV Infusion Rate of Combined Casirivimab (600 mg) and Imdevimab (600 mg) Diluted in 0.9% Sodium Chloride in Adults and Pediatric Patients 12 Years of Age or Older Weighing at Least 40 kg 1

...

Table 4. Recommended IV Infusion Rate of Combined Casirivimab (300 mg) and Imdevimab (300 mg) Diluted in 0.9% Sodium Chloride in Adults and Pediatric Patients 12 Years of Age or Older Weighing at Least 40 kg 1

...

Sub-Q Injection

...

Casirivimab and Imdevimab (Co-formulated)

...

Casirivimab and Imdevimab (Supplied in Separate Vials)

...

Dosage

...

Adult Dosage

...

Treatment of Coronavirus Disease 2019 (COVID-19)

...

Prevention of Coronavirus Disease 2019 (COVID-19)

...

Pediatric Dosage

...

Treatment of Coronavirus Disease 2019 (COVID-19)

...

Prevention of Coronavirus Disease 2019 (COVID-19)

...

Special Populations

...

Hepatic Impairment

...

Renal Impairment

...

...

Cautions

Cautions

...

Contraindications

...

Warnings/Precautions

...

Sensitivity and Infusion-related Reactions

...

Clinical Worsening after Casirivimab and Imdevimab Administration

...

Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19

...

EUA Requirements for Patient Monitoring and Mandatory FDA MedWatch Reporting

...

Specific Populations

...

Pregnancy

...

Lactation

...

Pediatric Use

...

Geriatric Use

...

Hepatic Impairment

...

Renal Impairment

...

Common Adverse Effects

...

...

Drug Interactions

Drug Interactions

...

Vaccines

...

COVID-19 Vaccines

...

...

Pharmacokinetics

Pharmacokinetics

...

Absorption

...

Distribution

...

Elimination

...

Special Populations

...

...

Stability Section

Stability

...

Solution for IV Infusion or Sub-Q Injection

...

...

Advice to Patients

Advice to Patients

...

...

Preparations

Preparations

...

Casirivimab

...

Imdevimab

...

Casirivimab and Imdevimab

...

...

Common general statement Elements

Additional Information

...

...

References

References

...

...

Copyright

AHFS® Drug Information. © Copyright, 1959-2021, Selected Revisions August 16, 2021. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

Quelle

AHFS Drug Information